Daily pill helps prevent HIV infection in men

A once-daily pill can protect men at high risk of HIV from becoming infected, a ground-breaking study showed on Wednesday.

The international trial, which has generated much excited anticipation, provides proof for the first time that pills used to treat HIV/Aids can also prevent it. Campaigners greeted the results — published on Wednesday in the New England Journal of Medicine — with enthusiasm, suggesting that they could fundamentally change the approach to preventing HIV in some groups of people.

The findings are good news for men who have sex with men, the population in whom the drugs were tried. There were 43,8% fewer HIV infections among those who took Truvada, the once-a-day tablet containing two drugs, emtricitabine and tenofovir, than among those who did not. The protective effect was much greater in those who took the tablets consistently: it reduced the risk of those who took it 90% or more of the time by 72,8%.

But Aids experts warned gay and bisexual men and their doctors that drugs did not offer an instant and easy answer. Protection was low in those who did not take them regularly. The Centres for Disease Control in the United States issued guidance that pre-exposure prophylaxis “should never be seen as the first line of defence against HIV”. Men who participated in the trials were counselled to use condoms, reduce their number of sexual partners and get tested and treated for other sexually transmitted diseases which can increase the risk of HIV infection.

No answers for women
The big unanswered question is whether drugs can also prevent infection in other at-risk groups, such as women in sub-Saharan Africa whose partners will not use condoms, and drug users. The study showed the pill is protective in sex between men, but it does not follow that drugs would protect during heterosexual sex, where the route of transmission is different.

Other studies are under way in heterosexual couples and in injecting drug users, however, and there is some reason for hope. One of the drugs used in this trial, tenofovir, has been shown to prevent some HIV infections in women when it is applied to the vagina as a gel before sex.

Dr Kevin Fenton, director of the CDC National Centre for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, said the results “represent a major advance in HIV prevention research … Given the heavy burden of HIV among gay and bisexual men, a new tool with potential additive benefit is exciting and welcome news.”

The findings provided hope that prophylactic drug treatment could protect other at-risk groups around the world. “Given the continued severity of the HIV epidemic, safe and effective new approaches are urgently needed for all populations at risk,” he said.

Aids campaigners called for swift action on the findings. More clinical research is needed, said Chris Collins, the vice president of Amfar (the Foundation for Aids Research), “but given the severity of the MSM epidemic, we also need to move forward with implementation studies that can assess adherence, safety, and the potential to impact HIV incidence”.

He and the CEO, Kevin Frost, hoped that the findings would help make the case for continuing high levels of Aids research in spite of the economic downturn. “If we’re serious about controlling this epidemic, we need to continue to make those investments,” said Frost.

The study was carried out by the independent Gladstone Institute on behalf of the US National Institutes of Health in six countries: Brazil, Ecuador, Peru, South Africa, Thailand and the United States. Nearly 2 500 men and transgender women who have sex with men and were at high risk of HIV infection took part in the study which began in 2007. Half the volunteers were given Truvada and the others were given a dummy pill. — Guardian

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever. But it comes at a cost. Advertisers are cancelling campaigns, and our live events have come to an abrupt halt. Our income has been slashed.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years. We’ve survived thanks to the support of our readers, we will need you to help us get through this.

To help us ensure another 35 future years of fiercely independent journalism, please subscribe.


‘Tenderpreneurs’ block the delivery of protective equipment to schools

Protests by local suppliers have delayed PPE delivery, which according to the DBE, is one of the reasons the reopening of schools has been pushed back until June 8

‘Soon he’ll be seen as threatening, not cute’: What it’s...

There is no separating George Floyd’s killing from the struggles black people have faced ever since the first slave ships landed on these shores

How schools could work during Covid

Ahead of their opening, the basic education department has given schools three models to consider to ensure physical distancing

Press Releases

Mining company uses rich seam of technology to gear up for Covid-19

Itec Direct technology provides instant temperature screening of staff returniing to the workplace with no human contact

Covid-19 and Back to School Webinar

If our educators can take care of themselves, they can take care of the children they teach

5G technology is the future

Besides a healthcare problem Covid-19 is also a data issue and 5G technology, with its lightning speed, can help to curb its spread

JTI off to court for tobacco ban: Government not listening to industry or consumers

The tobacco ban places 109 000 jobs and 179 000 wholesalers and retailers at risk — including the livelihood of emerging farmers

Holistic Financial Planning for Professionals Webinar

Our lives are constantly in flux, so it makes sense that your financial planning must be reviewed frequently — preferably on an annual basis

Undeterred by Covid-19 pandemic, China and Africa hold hands, building a community of a shared future for mankind

It is clear that building a community with a shared future for all mankind has become a more pressing task than ever before

Wills, Estate Administration and Succession Planning Webinar

Capital Legacy has had no slowdown in lockdown regarding turnaround with clients, in storing or retrieving wills and in answering their questions

Call for Expression of Interest: Training supply and needs assessment to support the energy transition in South Africa

GIZ invites eligible and professional companies with local presence in South Africa to participate in this tender to support the energy transition

The best local and international journalism

handpicked and in your inbox every weekday